Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Articles

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan E. Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A. Nebhan, Paula J. Spitzler, Jonathon P. Orme, M. Raymond V. Finlay, Richard A. Ward, Martine J. Mellor, Gareth Hughes, Amar Rahi, Vivien N. Jacobs, Monica Red Brewer, Eiki Ichihara, Jing Sun, Hailing Jin, Peter Ballard, Katherine Al-Kadhimi, Rachel Rowlinson, Teresa Klinowska, Graham H.P. Richmond, Mireille Cantarini, Dong-Wan Kim, Malcolm R. Ranson and William Pao
Darren A.E. Cross
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Darren.Cross@astrazeneca.com william.pao@vanderbilt.edu
Susan E. Ashton
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serban Ghiorghiu
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cath Eberlein
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline A. Nebhan
4Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula J. Spitzler
4Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathon P. Orme
2Discovery Sciences, AstraZeneca, Macclesfield Cheshire;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Raymond V. Finlay
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard A. Ward
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martine J. Mellor
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gareth Hughes
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amar Rahi
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vivien N. Jacobs
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Red Brewer
4Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eiki Ichihara
4Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Sun
4Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hailing Jin
4Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Ballard
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Al-Kadhimi
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Rowlinson
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Klinowska
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham H.P. Richmond
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mireille Cantarini
1Oncology Innovative Medicines and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dong-Wan Kim
5Seoul National University Hospital, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malcolm R. Ranson
3University of Manchester, Christie Hospital, Manchester, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Pao
4Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Darren.Cross@astrazeneca.com william.pao@vanderbilt.edu
DOI: 10.1158/2159-8290.CD-14-0337 Published September 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: June 2014 to January 2021

AbstractFull-text HTMLPDF
Total172463916429536

Cited By

Article Information

Volume 4, Issue 9, pp. 1046-1061

DOI 
https://doi.org/10.1158/2159-8290.CD-14-0337
PubMed 
24893891

Published By 
American Association for Cancer Research
Print ISSN 
2159-8274
Online ISSN 
2159-8290
History 
  • Received March 31, 2014
  • Revision received June 1, 2014
  • Accepted June 2, 2014
  • Published first June 3, 2014.

Article Versions

  • Previous version (June 3, 2014 - 06:46).
  • Previous version (June 5, 2014 - 07:30).
  • Previous version (August 11, 2014 - 08:07).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2014 American Association for Cancer Research.

Author Information

  1. Darren A.E. Cross1,*,
  2. Susan E. Ashton1,
  3. Serban Ghiorghiu1,
  4. Cath Eberlein1,
  5. Caroline A. Nebhan4,
  6. Paula J. Spitzler4,
  7. Jonathon P. Orme2,
  8. M. Raymond V. Finlay1,
  9. Richard A. Ward1,
  10. Martine J. Mellor1,
  11. Gareth Hughes1,
  12. Amar Rahi1,
  13. Vivien N. Jacobs1,
  14. Monica Red Brewer4,
  15. Eiki Ichihara4,
  16. Jing Sun4,
  17. Hailing Jin4,
  18. Peter Ballard1,
  19. Katherine Al-Kadhimi1,
  20. Rachel Rowlinson1,
  21. Teresa Klinowska1,
  22. Graham H.P. Richmond1,
  23. Mireille Cantarini1,
  24. Dong-Wan Kim5,
  25. Malcolm R. Ranson3 and
  26. William Pao4,*
  1. 1Oncology Innovative Medicines and
  2. 2Discovery Sciences, AstraZeneca, Macclesfield Cheshire;
  3. 3University of Manchester, Christie Hospital, Manchester, United Kingdom;
  4. 4Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and
  5. 5Seoul National University Hospital, Seoul, Republic of Korea
  1. ↵*Corresponding Authors:
    Darren Cross, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom. Phone: 44-1625-515649; E-mail: Darren.Cross{at}astrazeneca.com; and William Pao, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232. Phone: 615-343-9454; Fax: 615-343-7602; E-mail: william.pao{at}vanderbilt.edu
View Full Text
PreviousNext
Back to top
Cancer Discovery: 4 (9)
September 2014
Volume 4, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A.E. Cross, Susan E. Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A. Nebhan, Paula J. Spitzler, Jonathon P. Orme, M. Raymond V. Finlay, Richard A. Ward, Martine J. Mellor, Gareth Hughes, Amar Rahi, Vivien N. Jacobs, Monica Red Brewer, Eiki Ichihara, Jing Sun, Hailing Jin, Peter Ballard, Katherine Al-Kadhimi, Rachel Rowlinson, Teresa Klinowska, Graham H.P. Richmond, Mireille Cantarini, Dong-Wan Kim, Malcolm R. Ranson and William Pao
Cancer Discov September 1 2014 (4) (9) 1046-1061; DOI: 10.1158/2159-8290.CD-14-0337

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A.E. Cross, Susan E. Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A. Nebhan, Paula J. Spitzler, Jonathon P. Orme, M. Raymond V. Finlay, Richard A. Ward, Martine J. Mellor, Gareth Hughes, Amar Rahi, Vivien N. Jacobs, Monica Red Brewer, Eiki Ichihara, Jing Sun, Hailing Jin, Peter Ballard, Katherine Al-Kadhimi, Rachel Rowlinson, Teresa Klinowska, Graham H.P. Richmond, Mireille Cantarini, Dong-Wan Kim, Malcolm R. Ranson and William Pao
Cancer Discov September 1 2014 (4) (9) 1046-1061; DOI: 10.1158/2159-8290.CD-14-0337
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Methods
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Genetically Defined High-Grade Serous Ovarian Cancer Models
  • Personalized Antibodies for Gastroesophageal Adenocarcinoma
  • Fibroblastic NetG1 Promotes Pancreatic Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement